Farma
08.07.2021 kl 08:09
11351
FDA Fast Tracks
@targovax
ONCOS-102 vs PD-1-refractory #melanoma, supporting upcoming Ph2 #ClinicalTrials
Studies show #oncolytic #adenovirus delivering #GM_CSF activates innate #immunity vs #tumors
https://targovax.com/en/melanoma/
#immunooncology
@LHA_IR_PR
https://twitter.com/DDNewsOnline
@targovax
ONCOS-102 vs PD-1-refractory #melanoma, supporting upcoming Ph2 #ClinicalTrials
Studies show #oncolytic #adenovirus delivering #GM_CSF activates innate #immunity vs #tumors
https://targovax.com/en/melanoma/
#immunooncology
@LHA_IR_PR
https://twitter.com/DDNewsOnline
Redigert 08.07.2021 kl 08:09
Rapportér innlegg
Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.